These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 9513825)

  • 21. Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy.
    Klinkenberg-Knol EC; Meuwissen SG
    Digestion; 1992; 51 Suppl 1():44-8. PubMed ID: 1356868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there any acid peptic disease that is refractory to proton pump inhibitors?
    Bardhan KD
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():13-24, discussion 29-31. PubMed ID: 8490075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
    Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
    Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis.
    James OF; Parry-Billings KS
    Age Ageing; 1994 Mar; 23(2):121-6. PubMed ID: 8023719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    McTavish D; Buckley MM; Heel RC
    Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study.
    Laursen LS; Havelund T; Bondesen S; Hansen J; Sanchez G; Sebelin E; Fenger C; Lauritsen K
    Scand J Gastroenterol; 1995 Sep; 30(9):839-46. PubMed ID: 8578181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Audit of reflux oesophagitis at 4 years.
    Pace F; Bollani S; Manzionna G; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):355-60. PubMed ID: 9789126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory peptic ulcers.
    Arakawa T; Kobayashi K; Dajani EZ
    J Assoc Acad Minor Phys; 1992; 3(3):95-102. PubMed ID: 1386767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.
    Koop H; Hotz J; Pommer G; Klein M; Arnold R
    Aliment Pharmacol Ther; 1990 Dec; 4(6):593-9. PubMed ID: 1983342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
    Bianchi-Porro G; Pace F; Sangaletti O; Peracchia A; Bonavina L; Vigneri S; Termini R
    Am J Gastroenterol; 1991 Nov; 86(11):1585-7. PubMed ID: 1951234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
    Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
    Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cimetidine and ranitidine in the treatment of reflux esophagitis].
    Kimmig JM
    Z Gastroenterol; 1984 Aug; 22(8):373-8. PubMed ID: 6091353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].
    Di Mario F; Grasso GA; Battaglia G; De Boni M; Vianello F; De Bona M; Pasquino M; Chiozzini G; Saggioro A
    Minerva Gastroenterol Dietol; 1993 Jun; 39(2):83-7. PubMed ID: 8364105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper non-variceal bleeding.
    Mohamed SA; al Karawi MA
    Hepatogastroenterology; 1996; 43(10):863-5. PubMed ID: 8884305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
    Klinkenberg-Knol EC; Meuwissen SG
    Digestion; 1989; 44 Suppl 1():47-53. PubMed ID: 2575061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.